BACKGROUND: Randomized trials show non-steroidal anti-inflammatory drugs (NSAIDs) reduce precancerous polyps. Observational studies of the NSAID aspirin (ASA) suggest that it reduces invasive colorectal cancer (CRC) incidence, but because ASA use may also be a marker for healthy behaviors, these studies may be subject to selection bias. We sought to estimate the effectiveness of NSAIDs in CRC prevention in the population of elderly Medicare beneficiaries, minimizing this selection bias.
INTRODUCTION
Colorectal cancer (CRC) is the fourth most common solid tumor and the second most common cause of cancer death. 1 The majority of CRCs are thought to arise as the result of a series of molecular changes that transform normal colonic epithelial cells to adenomatous polyps and, ultimately, to invasive cancers. A number of agents including NSAIDs, folic acid, calcium, and estrogens potentially inhibit polyp development and/or transformation into invasive cancer. 2 Of these,
NSAIDs have been the most widely studied. These agents inhibit both cyclooxygenase-1 and cyclooxygenase-2 (COX-2), enzymes involved in prostaglandin synthesis. COX-2 overexpression is thought to play an important role in colon carcinogenesis, as it is not elevated in normal colonic epithelium, but has been found to be elevated in 40% of colonic adenomas and up to 90% of sporadic CRC. 3, 4 Multiple randomized controlled trials (RCTs) [5] [6] [7] [8] [9] [10] [11] show
NSAIDs prevent polyps and numerous observational studies including case-control trials [12] [13] [14] , and cohort studies [15] [16] [17] suggest they also reduce the risk of subsequent invasive CRC by a similar magnitude. Estimates from both the polyp prevention trials and most observational studies of CRC risk suggest the effect size of NSAIDs on each of these end points to be between approximately 0.50 and 0.80. Whereas 2 RCTs and one recent cohort study have reported no association between NSAIDs and incident CRC [18] [19] [20] , the lower doses employed and/ or the shorter duration of use may explain the lack of effect. However, because regular use of the NSAID aspirin may be a marker of high-quality cardio-preventive care and other healthy behaviors, the lower risk of CRC among "NSAID users" in observational studies could be due to selection bias and unmeasured confounding related to the subset taking aspirin. Given the greater use of NSAIDS by patients with osteoarthritis (OA), we use existing data sources containing information about the associations between NSAIDS and OA and OA and CRC to provide a window into the effectiveness of NSAIDs in CRC prevention. Given that NSAID use among those with OA is more likely to be therapeutic (i.e., for pain management) rather than preventative, it is not likely to be a marker of receipt of preventive care. We similarly compare prior OA for female breast cancer cases and controls to explore whether an association between OA and these screening-detected cancers could be due to differential medical care.
MATERIALS AND METHODS

Data Sources
We used data from the 1993-1994 National Ambulatory Medical Survey (NAMCS) 21 to determine rates of NSAID use among elderly OA patients. NAMCS is an annual national sample survey of visits to office-based physicians that is designed to collect objective reliable information about the provision and use of ambulatory medical care services in the United States. It utilizes a multistage probability design with the physician-patient office visit as the sampling unit. Data include patient demographics, diagnoses, and current medications, both over-the-counter and prescription. The National Center for Health Statistics oversees NAMCS and conducts data quality audits routinely and estimates the medical and drug coding error rate to be 0-1%. 22 We used data from the Survival Epidemiology and EndResults (SEER)-Medicare program to study the association between OA and subsequent CRC diagnoses in elderly Medicare beneficiaries and the association between OA and subsequent breast cancer diagnoses among elderly female Medicare beneficiaries. The SEER-Medicare data are an NCI-sponsored linkage of the clinical data collected by the SEER registries with health services billing claims collected by Medicare for administrative purposes 23 . The SEER program collects information regarding the diagnosis and treatment of patients with cancer from 11 geographically diverse tumor registries to monitor trends in incidence and survival 24 . 
NSAID use by OA Diagnosis
We studied 18,379 patient-physician office visits within NAMCS data over 1993-1994 to determine the magnitude of the association between a diagnosis of OA and NSAID use among the elderly. Specifically, we restricted our analysis to those visits with patients aged 65 or older on the day of the visit. We evaluated the physician diagnostic fields for the presence of ICD-9-CM code 715 indicating "osteoarthritis and allied disorders" and each of the generic medication fields for the presence of 1 of 26 possible NSAIDs (Appendix).
CASE/CONTROL STUDY Disease Ascertainment
We used the SEER file to identify male and female patients who had been diagnosed with pathologically confirmed stage I-IV adenocarcinoma of the colon or rectum and female patients who had been diagnosed with pathologically confirmed stage I-IV carcinoma of the breast in 1995 (i.e., 1/1/95 to 12/30/95). We included all patients who were at least 68 years of age on 1/1/95, continuously enrolled in both Medicare parts A and B, and not enrolled in an HMO in the 36 months preceding disease status ascertainment. Date of disease ascertainment was the date of diagnosis for the cases operationalized as the first day of the month (i.e., January-December) and year (i.e., 1995) of diagnosis as reported in SEER. The final analytic sample of cases consisted of 4,599 individuals with CRC and 4,250 individuals with breast cancer. We used SEER-Medicare's 5% random sample of Medicare patients to identify appropriate control patients (i.e., those without histories of CRC or breast cancer). As we did for cases, we required that controls were at least 68 years of age on 1/1/ 95, had continuous enrollment in Medicare parts A and B, and were not enrolled in an HMO in the 36 months preceding disease status ascertainment (1/1/92-1/1/95). To ensure that the control group did not include patients with the cancers of interest (i.e., breast and CRC), we restricted our controls to those without either SEER or Medicare diagnoses for CRC or breast cancer in inpatient or ambulatory Medicare files in the 3 years before their inclusion in the analysis. Date of disease ascertainment was January 1, 1995 for all controls. The final analytic sample of controls consisted of 100,270 male and female individuals for comparison to CRC cases and 59,418 female individuals for comparison to breast cancer cases.
Exposure Ascertainment
For each case and control, we used the inpatient and ambulatory files to identify a diagnosis of osteoarthritis (ICD-9-CM 715) in the 36 months preceding disease status ascertainment. Prior work using these codes estimates that the positive predictive value of ICD-9 code 715 for osteoarthritis in the NCH file is 0.83. 26 Additionally, files were used to identify the procedure "total knee replacement" (CPT codes 27447, 27487, or 27486 and ICD-9 procedure codes 8154 or 8155) occurring in the 36 months preceding disease status ascertainment in the manner similar to Mahomed et al. 27 The procedure total knee replacement (TKR) was evaluated because it has a high correlation with OA. 28 For cases, this represented 3 years or 36 months before CRC or breast cancer diagnosis, and for controls, this represented an equivalent calendar period (i.e., 36 months before January 1, 1995).
Other Explanatory Variables
The Medicare denominator file provided information regarding age, sex, and race for cases and controls.
Evaluation of Differential Preventive Care for OA Patients
In addition to our comparison of OA among breast cancer cases and controls, we directly evaluated for the possibility and importance of differential endoscopic removal of polyps among the OA patients compared to non-OA patients. We estimated the proportion of those in our sample with large bowel endoscopy in the 3 years before disease ascertainment according to OA history and then evaluated the robustness of our key models to the addition of antecedent large bowel endoscopy.
We operationalized large bowel endoscopy as the presence of CPT codes 44388-44394, 45330-45339, 45378-45385; HCPCS codes G0104, G0105, G0120; and ICD-9 procedure codes 4522-4525, 4542, 4543 in Medicare files.
Statistical Analyses
With NAMCS data, we determined the proportion of patientphysician visits of elderly patients where both NSAIDs and OA were noted. We applied sampling weights provided by the NCHS to adjust survey estimates to the population level. We tested the equivalence of proportion of NSAID use by OA history with a chi-squared test.
With SEER-Medicare data, we calculated the odds of a CRC diagnosis according to whether or not individuals had claims for OA in the 3 years preceding disease status ascertainment. We calculated the odds of a breast cancer diagnosis according to whether or not females had claims for OA in the 3 years preceding disease status ascertainment. We also calculated the odds of a CRC diagnosis according to whether or not individuals had claims for TKR in the 3 years preceding disease status ascertainment. All estimates were adjusted for age, sex, and race. All analyses were performed in STATA 8.0 SE (College Station, Texas).
RESULTS
OA and NSAID Use
Among the 18,379 patient-physician office visits studied, OA was recorded in an estimated 5% of all visits in both years, and an NSAID was recorded in 10% of all visits in both years. In 1993, 39% (95%CI, 32-48%) of visits with a recorded OA diagnosis also had an NSAID drug listed as an active medication. Among the remaining 1993 physician-patient visits (i.e., those where a diagnosis of OA was not recorded for the patient), only 9% (95%CI, 8-10%) had an NSAID drug listed as an active medication. The chi-squared test for the comparison of proportion of NSAID use according to OA status had p<0.001. Results are similar for 1994. Thus, the expected difference in prevalence of NSAID use between visits with OA and visits without OA during these 2 years was 29%.
We then determined the expected NSAID-mediated CRC reduction associated with a diagnosis of OA by applying our estimate of 29% differential use of NSAIDs by OA patients to the reported range of risk reductions from RCTs of polyps. The lower bound of our estimate was 6% (RR 0.94) or 29% of the smallest risk reduction reported (i.e., 0.81) 29 , and the upper bound was 16% (RR 0.84) or 29% of the largest risk reduction reported (i.e., 0.44). 30 Thus, we estimate a diagnosis of OA in the elderly would be associated with a 6-16% decrease in CRC (i.e., RR 0.84-0.94). Table 2 ). We evaluated for and found no interaction between sex and OA (results not shown).
Case-Control Study
History of TKR and CRC
During the 36-month ascertainment period, 38 of 4,599 CRC patients (prevalence of 83/1,000) compared with 1,381 of 100,270 control patients (prevalence of 138/1,000) had ICD-9-CM codes indicating an antecedent TKR (Fisher's exact p= 0.001). The unadjusted OR of an antecedent TKR procedure among those with newly diagnosed CRC compared to the control group was 0.60 (95%CI, 0.43-0.82), and when adjusted for demographics, the OR was 0.61 (95%CI, 0.44-0.85; Table 2 ).
History of OA and Breast Cancer
During the 36-month ascertainment period, 1,477 of 4,250 breast cancer patients (prevalence of 348/1,000) compared with 20,687 of 59,418 female control patients (prevalence of 348/1,000) had ICD-9-CM codes indicating an antecedent OA (Fisher's exact p=0.947). The unadjusted OR of an antecedent OA diagnosis among those with newly diagnosed breast cancer compared to the female control group was 1.00 (95%CI, 0.93-1.06), and when adjusted for demographics, the OR was 0.99 (95%CI, 0.92-1.05; Table 2 ).
History of TKR and Breast Cancer
During the 36-month ascertainment period, 68 of 4,250 breast cancer patients (prevalence of 16/1,000) compared with 879 of 
001).
While we found that antecedent large bowel endoscopy was itself associated with a 26% reduction in odds of CRC diagnosis (OR 0.74; 95%CI, 0.67-0.81), we also found that its addition to the model only modestly changed the magnitude of the association between antecedent OA and CRC (OR 0.84; 95%CI, 0.78-0.90; see Table 3 ). Thus, whereas those with histories of OA are more likely to undergo large bowel endoscopy, the association between OA and CRC that we describe does not appear to be mediated by endoscopic polyp removal.
DISCUSSION
We find that elderly Medicare beneficiaries with OA have 15% lower odds of being diagnosed with CRC than those beneficiaries without this diagnosis (OR 0.85; 95%CI, 0.80-0.91). We also find that the magnitude of the odds reduction is similar to what would be expected from the estimated excess use of NSAIDs by those with OA (expected risk reduction 0.84-0.94). The TKR analyses support the association, and the breast cancer and large bowel endoscopy analyses suggest little confounding by differential health care or preventive health behaviors. Taken together, results suggest that NSAID chemoprevention may explain the reduced odds of developing CRC among elderly Medicare beneficiaries with OA.
Our findings have large public health implications, as they support the hypothesis that some portion of the secular decreases in the incidence of CRC over the last 20 years are attributable to secular increases in NSAID use (Lamont and Dias, under review). Since the NSAID ibuprofen was approved by the Federal Drug Administration (FDA) for over-the-counter marketing in 1984, the incidence of CRC has fallen approximately 13%, from 57/100,000 persons in 1985 to 49/100,000 persons in 2002. Given our estimates of 10% NSAID use reported among all elderly patient-physician visits, it is conceivable that as much as 46% of the decrease in CRC incidence (i.e., 6 percentage point absolute reduction) may be related to NSAID use. Further, our results suggest that there is likely a very large, previously occult and apparently accidental force of cancer prevention within the population of elderly Americans that has more to do with symptomatic treatment of a common comorbidity associated with aging than with physicians' purposeful targeted anticancer intervention. However, given well-described risks associated with NSAIDs (e.g., bleeding, kidney damage), we agree with the United States Preventative Services Task Force that NSAIDs should not be used by average risk individuals with the intent of preventing CRC. 31 Whereas routine use of NSAIDs for CRC prevention is currently limited only to a small group of individuals with high risk of CRC (e.g., those with familial CRC syndromes), this research does support the importance of further pharmacologic research directed at developing less toxic preventive agents whose risk and benefit profile would support broader use by lower risk individuals.
Our findings are consistent with prior studies reporting variation in CRC risk by sex and race. Relative to men, women had 16% lower odds of being diagnosed with CRC, which is similar to results from the national endoscopy database and likely relate to protective effects of endogenous and exogenous [e.g., hormone replacement therapy (HRT)] estrogens. 32 Our finding of 46% higher odds of developing CRC for blacks relative to whites is consistent with multiple previous reports. [33] [34] [35] A comparative advantage of this study over more traditional observational studies on this topic is that it minimizes confounding related to preventive medical care. For example, among cohorts of otherwise healthy individuals, aspirin use for persons aged 50 and older may be a marker of high-quality preventive care, and thus, negative associations between this NSAID and subsequent CRC may be confounded by a variety of factors including low-fat diet, exercise, and cancer screening. Because we focus on patients who are taking NSAIDs for There are limitations to the study related to the data sources. With respect to the NAMCS data, the sampling frame includes the entire US (not just SEER regions), information pertains to ambulatory visits by individuals who seek medical care, and the unit of analysis is distinct patient-physician encounters, not necessarily distinct patients, which could lead us to underestimate the size of the confidence by failing to account for the clustering of encounters within individual patients. Further, type, dose and duration of NSAID use are not available in this data source. Limitations to Medicare data include shortcomings in race coding, inconsistent information on HMO enrollees, and lack of certain relevant clinical variables (e.g., smoking history, family history, fat intake, obesity, physical activity, HRT). [36] [37] [38] [39] Given that prior research has shown that HRT use is more common among women with OA than women without OA, our results, showing a lack of a sex/OA interaction, is reassuring on this matter. 40 Similarly, given that prior research has shown that individuals with OA are more likely to smoke, to have high body mass indexes, and be inactive, we would expect these unmeasured confounders to spuriously attenuate the CRC-OA association (i.e., favor the null hypothesis of no association). [41] [42] [43] Finally, the 3-year look-back that we impose is not long enough to fully track CRC screening. In summary, analysis of observational data sources show that elderly Medicare beneficiaries with histories of OA are less likely to be diagnosed with invasive CRC relative to those without histories of OA. Furthermore, the magnitude of the CRC odds reduction associated with a diagnosis of OA is consistent with what would be expected from the observed greater use of NSAIDs among elderly individuals with OA. This research suggests that NSAIDs may be effective in the prevention of CRC in the population of elderly Medicare beneficiaries. 
